Objective: The expressions of minichromosome maintenance protein 2 (MCM2), and p53 were examined to analyze their pathobiological significance in human lung adenocarcinomas. Methods: We performed Western blot analysis in six human lung adenocarcinoma cell lines and immunohistochemistry in 145 surgically removed adenocarcinomas to examine the MCM2 expression. Labeling indices (LIs; %) of MCM2, Ki-67, and p53 in the tumor cells were compared with clinicopathological profiles and overall survival rates. Results: MCM2 protein was detected in all cell lines examined, with specific bands. MCM2 LIs were significantly correlated with sex, histological type, differentiation, pathological stage, and LIs of Ki-67 and p53 (p ! 0.05). Significantly higher LIs of MCM2 and Ki-67 were noted in the 122 non-pure bronchioloalveolar carcinomas than in the 23 pure bronchioloalveolar carcinomas (p ! 0.01), and the prognosis was poorer in the former than in the latter (p ! 0.01). Sex, pathological stage, and high LIs of MCM2 and/or Ki-67 were independent prognostic factors (p ! 0.05). Conclusion: High LIs of MCM2 and/or Ki-67 suggest a poor prognosis in patients with lung adenocarcinoma (non-pure bronchioloalveolar carcinoma).
Introduction
Lung cancer is the leading cause of cancer deaths in the world, with over 1,000,000 cases diagnosed every year [1] . Histopathologically, lung cancer is divided into two major types: small-cell lung cancer and non-small-cell lung cancer (NSCLC), the latter consisting of adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. Adenocarcinoma is the most frequent type in NSCLCs, developed from Clara cells or type II pneumocytes. Surgery is the first choice for patients with early-stage cancer, while patients with advanced disease undergo surgery, chemotherapy, radiation therapy, or a combination of them. Despite such treatment, the 5-year survival rate of pa-Hashimoto/Araki/Osaki/Nakamura/ Tomita/Shimizu/Ito tients with NSCLC remains low [2] , implying the need for more effective strategies for early diagnosis and new types of markers. Many previous studies have investigated proliferation-associated markers as potential candidates for prognostic factors in human lung cancer. Such factors include p53 overexpression [3] , the combination analysis of proliferating cell nuclear antigen and argyrophilic nucleolar organizer regions, and expression of cyclin E, Ki-67, ras P21, epidermal growth factor receptor, insulin-like growth-factor-binding proteins, and human telomerase reverse-transcriptase catalytic subunits [4] [5] [6] [7] [8] [9] . However, these factors have not been regarded as sufficient markers to predict a patient's prognosis.
Minichromosome maintenance proteins (MCM) were first found in yeast and then in eukaryotes [10, 11] . They constitute a family of at least six different nuclear proteins, MCM 2-7 [12] , which share an extensive sequence similarity in a central 200 amino acid region. They are known as the replication-licensing factor of DNAs, and they form the prereplicative complex with origin recognition complex and other licensing factors, cdc6/18 and cdt1 [13] [14] [15] , that control DNA replication, allowing it to occur only once per cell cycle [16] . MCM proteins are also regarded as cell-proliferative markers [17] , and their expression has been reported in many malignant neoplasms, including prostatic cancers [18] , oligodendrogliomas [19] , malignant fibrous histiocytomas [20] , and bladder cancers [21] . These reports have suggested a possible prognostic significance of such expression. Todorov et al. [22] examined various human tumors and detected MCM2 by immunoblotting in 70 of 72 various human tumors. This contrasts with only 6 cases of MCM2 expression in 27 normal tissue samples. Four lung adenocarcinomas were examined, and three samples showed MCM2 expression [22] . Recently, we generated a new monoclonal antibody against the N terminal of MCM2 (clone 2H10), the specificity of which was identified by Western blot analysis in human cultured oral squamous cell carcinomas [23] and human malignant fibrous histiocytomas [20] . Immunohistochemistry revealed that MCM2 was confined to the nucleus in proliferating cells of human nonneoplastic oral mucosa and dysplastic or carcinoma cells [23] .
In this study, we investigate the correlation between the expression of MCM2 and that of Ki-67, as well as p53, in 145 human lung adenocarcinomas, comparing clinicopathological factors.
Materials and Methods

Cell Lines and Western Blot Analysis
The expression of MCM2 was examined in six human lung adenocarcinoma cell lines: A549, PC14, and RERF-LC-KJ (purchased from Riken Cell Bank, Tsukuba, Japan), LK87 and LCSC#1 (provided by the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan), and Ma-1 (provided by Dr. T. Hirashima, Osaka Prefectural Habikino Hospital, Osaka, Japan). RERF-LC-KJ was cultured in Roswell Park Memorial Institute 1640 medium (RPMI 1640), and the others were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Life Technologies, Grand Island, N.Y., USA), 100 U/ml penicillin, 100 Ìg/ml streptomycin, and 292 Ìg/ml L-glutamine at 37°C in a humidified atmosphere with 5% CO 2 in air.
The subconfluent cells were rinsed in phosphate-buffered saline (PBS) and solubilized in lysis buffer [150 mM NaCl, 20 mM TrisHCl (pH 7.4), 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, and 1% Triton X-100, containing a mixture of proteinase inhibitors (5 Ìg/ml aprotinin, 1 Ìg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, and 1 mg/ml trypsin inhibitor)] for 60 min on ice.
Lysates were centrifuged at 12,000 rpm for 5 min. The protein concentrations were determined by the Bradford protein assay (Bio-Rad Laboratories, Hercules, Calif., USA), using bovine serum albumin as the standard. Equal amounts (30 Ìg) of proteins were resolved by electrophoresis on the 7.5% polyacrylamide gel and electrotransferred to the polyvinylidene difluoride filter membrane (Immobilon; Millipore, Waltham, Mass., USA). After blocking the nonspecific binding with 10% skim milk in PBS for 1 h at room temperature, the blotted membrane was incubated with anti-MCM2 (2H10, diluted 1:5) mouse monoclonal antibodies which were generated in our laboratory. Blots were developed with peroxidase-labeled antimouse antibody (1:1,000; MBL, Nagoya, Japan), using enhanced chemiluminescence (ECL detection system; Amersham Pharmacia Biotech, Amersham, UK).
Patients and Tissue Specimens
One hundred and forty-five lung adenocarcinoma tissue samples, comprising 23 pure bronchioloalveolar carcinomas (pure-BACs) and 122 non-pure bronchioloalveolar carcinomas (non-pure-BACs), were obtained from the archive of our Department of Pathology. Nonpure-BACs consisted of 70 with mixed subtypes, 31 with papillary types, 19 with acinar types, and 2 solid adenocarcinomas with mucin. All patients had undergone surgery with regional lymph node dissection between 1980 and 2001 at the Department of Thoracic Surgery, Yonago National Hospital, Tottori, Japan. None of the patients had received preoperative chemotherapy or radiotherapy. All tumors were clinically localized diseases without preoperative evidence of distant metastases. The resected specimens were fixed in 10% neutral-buffered formalin and embedded in paraffin. Histological diagnoses and tumor stages were made according to the classifications of the Union Internationale Contre le Cancer (UICC) and the World Health Organization (WHO) [24, 25] . We obtained approval for this study from the Institutional Review Board of the Faculty of Medicine, Tottori University (Approval No. 283).
Immunohistochemistry
Tissue sections (3 Ìm) were dewaxed in xylene, rehydrated through a graded series of ethanol solutions, rinsed in distilled water for 5 min, and then immersed in 0.6% hydrogen peroxide (H 2 O 2 ) in methanol for 30 min to block endogenous peroxidase. For antigen retrieval, the sections were then microwaved in 0.01 mol/l of sodium citrate buffered saline (pH 6.0) for 20 min at 92°C, using a microwave processor model MI-77 (Azumaya, Japan). After being rinsed in PBS for 5 min, the slides were preblocked with 10% normal rabbit serum at room temperature for 20 min and incubated at 4°C overnight with mouse monoclonal antibodies as follows: anti-MCM2 antibody (2H10, 1:5), anti-Ki-67 antibody (MIB-1, 1:50; DAKO, Glostrup, Denmark), and anti-p53 antibody (DO-7, 1: 50; Novocastra, Newcastle upon Tyne, UK) which mainly detects mutant p53 in immunohistochemistry. A subsequent reaction was initiated by the streptavidin-biotin-peroxidase complex technique (SAB method) using a Histofine SAB-PO (M) immunohistochemical staining kit (Nichirei, Tokyo, Japan). The immunoreaction was visualized with 3,3)-diaminobenzidine and 100 Ìl of hydrogen peroxide in 0.05 M TrisHCl buffer (pH 7.6). Finally, the slides were counterstained with 0.1% hematoxylin.
To evaluate MCM2, Ki-67, and p53 expression levels, positively stained tumor cell nuclei were counted in the most frequently and distinctly labeled areas. Labeling indices (LIs) were expressed as percentages of positively stained cells based on a count of at least 1,000 tumor cells. The percentage of positive cells was determined for each antibody by two of the authors (K.H. and K.A.). All cases were judged to be high for MCM2, Ki-67, and p53, when the LIs were more than 40, 20, and 10%, respectively.
Statistics
The differences of MCM2 and Ki-67 LIs between pure-BAC and non-pure-BAC were evaluated by the Mann-Whitney U test. Chisquare test and Fisher's exact test were used to evaluate the independence of a variety of clinicopathological profiles from MCM2 LIs. The survival rates were estimated by the Kaplan-Meier method [26] , and statistical analyses were carried out using the log-rank test. Univariate and multivariate Cox regression analyses were used to evaluate the contribution of various factors to the overall survival of the 122 patients with non-pure-BAC. p ! 0.05 was considered to be statistically significant.
Results
MCM2 Expression in Human Lung Adenocarcinoma Cell Lines
First, we examined the expression of MCM2 in the six human lung adenocarcinoma cell lines by Western blot analysis which showed two specific bands at 120 kD in all cell lines ( fig. 1 ). An upper band in each lane was considered as phosphorylated MCM2 protein, as reported previously [27, 28] . The expression level was highest in PC14, followed by LCSC#1, Ma-1, LK87, RERF-LC-KJ, and A549, in the order given.
MCM2 and Ki-67 LIs
MCM2 and Ki-67 immunoreactivities were noted exclusively in the nucleus of non-pure-BAC cells as well as in a few stromal lymphocytes ( fig. 2 ). On the other hand, a few positive cells were seen in the cases with pure-BAC. Most mitotic cells showed Ki-67 immunoreactivity, with no expression of MCM2. In most cases, MCM2 and Ki-67 LIs were significantly higher in the marginal area of the tumor than in the center. Therefore, we mainly observed the marginal areas for evaluation. Table 1 shows the mean MCM2 and Ki-67 LIs in the 23 pure-BACs and in the 122 non-pure-BACs. The mean LIs were 6.9 B 3.1 and 5.8 B 2.5% in the former and 46.6 B 2.7 and 33.0 B 2.2% in the latter, respectively. Both MCM2 and Ki-67 LIs were significantly higher in the non-pure-BACs than in the pure-BACs (p ! 0.01), suggesting that the proliferative activity of carcinoma cells was higher in the former than in the latter. In addition, the MCM2 LI was higher than that of Ki-67 in 141 of the 145 cases, regardless of the histological type. Table 2 shows the correlation of the clinicopathological profiles and the LIs of Ki-67 and p53 regarding the 69
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Hashimoto/Araki/Osaki/Nakamura/ Tomita/Shimizu/Ito patients with MCM2 LI high and the 76 patients with MCM2 LI low. The mean age of the patients was 63.3 (ranging from 33 to 89) years, but no significant correlation was noted between the two groups. Significantly higher MCM2 LIs were noted in males than in females (p = 0.02), in the non-pure-BACs than in the pure-BACs, and in moderately or poorly differentiated carcinomas than in well-differentiated carcinomas (p ! 0.01). Moreover, high MCM2 LIs were found in 30 (60.0%) of the 50 cases with stage III carcinoma as compared with 39 (41.1%) of the 95 cases at stages I and II (p ! 0.01). High MCM2 LIs were noted in 63 (82.9%) of the 76 carcinomas with high Ki-67 LIs and in 6 (8.7%) of the 69 carcinomas with low Ki-67 LIs, the frequency being significantly higher in the former than in the latter (p ! 0.01). Similarly, MCM2 LIs were significantly higher in the 72 carcinomas with high p53
LIs than in the 73 carcinomas with low p53 LIs (p ! 0.01). Figure 3 shows the overall survival curves of the 145 patients with lung adenocarcinomas (Kaplan-Meier estimates). The mean survival was 45.0 months in the 122 patients with non-pure-BAC and 83.2 months in the 23 patients with pure-BAC. Log-rank testing demonstrated their values to be significantly different (p ! 0.01).
Prognostic Analyses
Next, we performed univariate Cox regression analyses to evaluate the contribution of potential prognostic markers to the overall survival in the 122 patients with nonpure-BAC (table 3) Hashimoto/Araki/Osaki/Nakamura/ Tomita/Shimizu/Ito with non-pure-BAC (table 4) . Figure 4 shows the overall survival curves of the patients divided into two groups according to the MCM2 and Ki-67 LIs (Kaplan-Meier estimates). The log-rank test also revealed that patients with high LIs of MCM2 and/or Ki-67 showed a significantly poor prognosis (p ! 0.01). Although we tried to show the independence of MCM2 LIs alone or high LIs of MCM2 and/or Ki-67 using various cutoff values of MCM2 LI (every 10% from 10 to 90%), we could show significant data only when we used the '40%' cutoff value.
In the 23 pure-BACs, we could not analyze the prognostic value of high LIs of MCM2 and/or Ki-67, because only 2 cases showed them.
Discussion
It is well known that patients with localized, early-stage pure-BACs have a better outcome with curative surgery [29] . More recent studies [30, 31] have also revealed that patients with this type of tumor had favorable prognoses. We confirmed that patients with pure-BAC had a more favorable prognosis than those with non-pure-BAC. The different biological behaviors between the two types of adenocarcinoma may partly be explained by the proliferative activity of tumor cells. Both MCM2 and Ki-67 LIs, markers of the cell-proliferative activity, were significantly higher in the non-pure-BACs than in the pure-BACs. Attention should be paid to the non-pure-BACs to improve patients' prognoses by early detection or through new molecular targeting therapy.
Ramnath et al. [32] reported that MCM2 LI, but not the Ki-67 LI, was an independent and clinically significant prognostic parameter of survival in 221 patients with NSCLC. However, in the 122 patients with non-pure-BAC, we could show no evidence for the superiority of MCM2 LIs to Ki-67 LI as well as for the utility of MCM2 or Ki-67 LI alone as an independent prognostic marker. We considered that the small number of cases or the biological differences in histological types might not permit us to show such evidences. Despite the small patient number, MCM2 and/or Ki-67 expression proved to be independent in multivariate Cox regression analysis. Gerdes et al. [33] conducted an in vitro study on the correlation between the cell cycle and the Ki-67 expression. These authors showed that the Ki-67 expression during the G 1 phase varied: cells passing the early events of mitogentriggered transition from G 0 to G 1 lacked the Ki-67 nuclear antigen, whereas G 1 cells after mitosis were consistently Ki-67 positive. On the other hand, Shomori and colleagues [unpubl. data] detected MCM2 expression during the early G 1 phase which continued into the S and G 2 phases in an in vitro study using human fibroblast HFSKF-II cells. Moreover, they indicated that mitotic cells did not show MCM2 immunoreactivity in normal gastric mucosae, tubular adenomas, or advanced gastric carcinomas. They also confirmed no expression of Ki-67 during the early G 1 phase, whereas MCM2 was expressed at a relatively high level in HFSKF-II. Indeed, we found that most mitotic cells of lung adenocarcinomas showed Ki-67 immunoreactivity, in contrast to MCM2. Thus, we can consider that MCM2 expression is seen from the G 1 to the G 2 phase, while Ki-67 expression is seen in from the late G 1 phase to the mitotic phase. This explains that high LIs of MCM2 and/or Ki-67 reflect much more cells in the cell cycle than those of MCM2 or Ki-67 alone. We suggest that high a LI of MCM2 and/or Ki-67 is the most excellent marker to predict a patient's prognosis.
We confirmed that sex and pathological stage were also independent prognostic parameters for patients with nonpure-BAC. Alexiou et al. [34] reported a significant positive effect on overall survival after surgery in female patients with NSCLC. A longer survival period was also noted in female than in male patients with inoperable NSCLC who were treated with radiotherapy or chemotherapy [35, 36] . Although a few epidemiological and molecular explanations have been discussed regarding the better prognosis for female patients [37] [38] [39] [40] , the precise mechanism has not been fully clarified. However, many reports have confirmed the pathological stage as the most significant prognostic factor in NSCLCs [41] [42] [43] [44] [45] .
Finally, it is worth discussing the relationship between MCM2 and p53 expression, the latter of which has been shown to be required for the induction of an apoptotic pathway triggered by oncogenic activation and the expression of cytotoxic genes [46] . The protein might sensitize damaged cells to apoptosis and act to prevent the propagation of transforming mutations. Cells lacking a functional p53 protein would be refractory to this process of elimination and might proliferate more aggressively. The mutated p53 protein accumulates in the nucleus by binding to other oncogenic proteins, thus prolonging its halflife. Therefore, it is understandable that the LIs of MCM2 and p53 correlated. We could not, however, confirm the significant relationship between p53 LIs and patients' prognosis by both univariate and multivariate Cox regression analyses. It is controversial whether p53 alteration or expression is an independent indicator to predict an unfavorable prognosis in patients with NSCLC [3, 47] or not [48, 49] . This might be partly due to the small number of cases examined. Further studies are needed to clarify the pathobiological significance of p53 gene alteration in human lung carcinomas.
